• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Enzyme Replacement Therapy Adzynma Launches with $245,000 Annual Price

News
Article

Adzynma is a recombinant protein designed to replace the deficient ADAMTS13 enzyme to treat patients with the rare hereditary blood clotting disorder congenital thrombotic thrombocytopenic purpura

Takeda has launched Adzynma (ADAMTS13, recombinant-krhn) to treat adults and children with congenital thrombotic thrombocytopenic purpura (cTTP). The FDA granted approval to Adzynma in early November 2023 as a prophylactic or on-demand enzyme replacement therapy.

CTTP is rare hereditary blood clotting disorder stemming from a disease-causing mutation in the ADAMTS13 gene. This gene plays a crucial role in producing the ADAMTS13 enzyme, which is responsible for regulating blood clotting.

In people with cTTP, a deficiency in this enzyme leads to the formation of blood clots in small vessels throughout the body. This life-threatening condition, affecting fewer than one thousand people in the United States, typically begins in infancy or early childhood, with some cases emerging in adulthood or during pregnancy.

Adzynma is a purified recombinant form of the ADAMTS13 enzyme, designed to replace the insufficient levels of the deficient enzyme in cTTP patients. Administered as an injection, Adzynma serves both as a prophylactic ERT, to prevent disease symptoms, and as on-demand ERT, for acute events. The prophylactic regimen involves bi-weekly intravenous administrations, while on-demand treatment requires daily doses.

Cheryl Schwartz

Cheryl Schwartz

“For nearly a century, people impacted by this debilitating, ultra-rare condition have been without a treatment option specifically indicated for their disease,” Cheryl Schwartz, senior vice president, Rare Disease Business Unit at Takeda, said in a press release.

Related: FDA Approves Enzyme Replacement Therapy for Rare Clotting Disorder

Adzynma will have a list price of $3.28 per IU, or about $245,000 annually for a 72 kg patient receiving prophylactic treatment every other week, according to a Takeda spokesperson. The exact cost, however, will vary depending on patient weight and whether the patient is receiving prophylactic or on-demand treatment. Adzynma will be available through a network of specialty pharmacies and distributors.

Regardless of insurance status or benefit design, ensuring patients have access to the medicines they need is a top priority for Takeda, the spokesperson said. The company provides patient support programs that can assist eligible patients – both those with and without insurance – in accessing medicines.

The FDA approval was supported by the totality of the evidence provided by the analysis of efficacy, pharmacokinetic, safety and tolerability data from a phase 3 trial that enrolled 37 patients who received the enzyme therapy, as well as by data from the continuation trial. In the phase 3 trial, no patient treated with Adzynma experienced an acute TTP event.

The most common adverse reactions were headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.